ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia
Published: 15 Jun 2020
Views: 470
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Prof Constantine Tam talks to ecancer in an online interview for the ASCO virtual meeting 2020 about the ASPEN study.
Prof Tam outlines the study design which compares two BTK (bruton tyrosine kinase) inhibitors for the first time.
He discusses the results, which despite not reaching the primary endpoint, showed promise for zanubrutinib when it came to toxicities.
Related Videos
Promise of personalised medicine for patients with prostate cancer
Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt ...
26 Feb 2021
Long-term follow-up of low-intensity chemotherapy with combination therapy for r...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
22 Dec 2020
Latest data for managing ALK NSCLC patients
Prof Myung-Ju Ahn - Samsung Medical Center, Seoul, South Korea
11 Dec 2020
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
